These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20055079)

  • 1. Lipid nanomedicines for anticancer drug therapy.
    Estella-Hermoso de Mendoza A; Campanero MA; Mollinedo F; Blanco-Prieto MJ
    J Biomed Nanotechnol; 2009 Aug; 5(4):323-43. PubMed ID: 20055079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-based drug delivery systems for cancer treatment.
    Arias JL; Clares B; Morales ME; Gallardo V; Ruiz MA
    Curr Drug Targets; 2011 Jul; 12(8):1151-65. PubMed ID: 21443475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles.
    Wong HL; Bendayan R; Rauth AM; Li Y; Wu XY
    Adv Drug Deliv Rev; 2007 Jul; 59(6):491-504. PubMed ID: 17532091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrophobic ion pairing as a strategy to improve drug encapsulation into lipid nanocarriers for the cancer treatment.
    Oliveira MS; Goulart GCA; Ferreira LAM; Carneiro G
    Expert Opin Drug Deliv; 2017 Aug; 14(8):983-995. PubMed ID: 27892713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-polymer hybrid nanocarrier-mediated cancer therapeutics: current status and future directions.
    Garg NK; Tandel N; Jadon RS; Tyagi RK; Katare OP
    Drug Discov Today; 2018 Sep; 23(9):1610-1621. PubMed ID: 29857164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Fluorouracil shell-enriched solid lipid nanoparticles (SLN) for effective skin carcinoma treatment.
    Khallaf RA; Salem HF; Abdelbary A
    Drug Deliv; 2016 Nov; 23(9):3452-3460. PubMed ID: 27240935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives.
    Uner M; Yener G
    Int J Nanomedicine; 2007; 2(3):289-300. PubMed ID: 18019829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral lipid nanomedicines: Current status and future perspectives in cancer treatment.
    El Moukhtari SH; Rodríguez-Nogales C; Blanco-Prieto MJ
    Adv Drug Deliv Rev; 2021 Jun; 173():238-251. PubMed ID: 33774117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCL/PEG copolymeric nanoparticles: potential nanoplatforms for anticancer agent delivery.
    Gou M; Wei X; Men K; Wang B; Luo F; Zhao X; Wei Y; Qian Z
    Curr Drug Targets; 2011 Jul; 12(8):1131-50. PubMed ID: 21443476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vesicle-like structure of lipid-based nanoparticles as drug delivery system revealed by molecular dynamics simulations.
    Khalkhali M; Mohammadinejad S; Khoeini F; Rostamizadeh K
    Int J Pharm; 2019 Mar; 559():173-181. PubMed ID: 30684596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solid lipid based nanocarriers: an overview.
    Pardeshi C; Rajput P; Belgamwar V; Tekade A; Patil G; Chaudhary K; Sonje A
    Acta Pharm; 2012 Dec; 62(4):433-72. PubMed ID: 23333884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hansen solubility parameters (HSP) for prescreening formulation of solid lipid nanoparticles (SLN): in vitro testing of curcumin-loaded SLN in MCF-7 and BT-474 cell lines.
    Doktorovova S; Souto EB; Silva AM
    Pharm Dev Technol; 2018 Jan; 23(1):96-105. PubMed ID: 28949267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.
    Chen Z; Zheng Y; Shi Y; Cui Z
    Int J Nanomedicine; 2018; 13():319-336. PubMed ID: 29391792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To reduce premature drug release while ensuring burst intracellular drug release of solid lipid nanoparticle-based drug delivery system with clathrin modification.
    Li J; Sun L; Liu Y; Yao H; Jiang S; YunzhuPu ; Li Y; Zhang Y
    Nanomedicine; 2019 Jan; 15(1):108-118. PubMed ID: 29859268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on preparation and characterization of resveratrol solid lipid nanoparticles and its anticancer effects in vitro].
    Zhang QH; Xiong QP; Shi YY; Zhang DY
    Zhong Yao Cai; 2010 Dec; 33(12):1929-32. PubMed ID: 21548373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catanionic Hybrid Lipid Nanovesicles for Improved Bioavailability and Efficacy of Chemotherapeutic Drugs.
    Xie X; He D; Wu Y; Wang T; Zhong C; Zhang J
    Methods Mol Biol; 2021; 2211():57-68. PubMed ID: 33336270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-drug-conjugate (LDC) solid lipid nanoparticles (SLN) for the delivery of nicotine to the oral cavity - Optimization of nicotine loading efficiency.
    Ding Y; Nielsen KA; Nielsen BP; Bøje NW; Müller RH; Pyo SM
    Eur J Pharm Biopharm; 2018 Jul; 128():10-17. PubMed ID: 29545120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SLN for topical application in skin diseases--characterization of drug-carrier and carrier-target interactions.
    Küchler S; Herrmann W; Panek-Minkin G; Blaschke T; Zoschke C; Kramer KD; Bittl R; Schäfer-Korting M
    Int J Pharm; 2010 May; 390(2):225-33. PubMed ID: 20153414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Folate-Grafted Chitosan Derivative To Improve Delivery of Paclitaxel-Loaded Solid Lipid Nanoparticles for Lung Tumor Therapy by Inhalation.
    Rosière R; Van Woensel M; Gelbcke M; Mathieu V; Hecq J; Mathivet T; Vermeersch M; Van Antwerpen P; Amighi K; Wauthoz N
    Mol Pharm; 2018 Mar; 15(3):899-910. PubMed ID: 29341619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.